BioLineRx Ltd.
BLRX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BLRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BLRX
BioLineRx Ltd. is a biopharmaceutical company focused on oncology and rare diseases, with one FDA-approved product (APHEXDA) and a pipeline including motixafortide for pancreatic cancer and GLIX1, but faces significant financial challenges with a going concern qualification and accumulated losses of $401 million.
Key risk: Going concern risk
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
Tracking 4 clinical trials · 1 catalyst for BioLineRx Ltd..
BioLineRx Ltd. is a biopharmaceutical company focused on oncology and rare diseases, with one FDA-approved product (APHEXDA) and a pipeline including motixafortide for pancreatic cancer and GLIX1, but faces significant financial challenges with a going concern qualification and accumulated losses of $401 million.
- BioLineRx's first approved product, APHEXDA (motixafortide), was approved by the FDA on September 8, 2023, for stem cell mobilization in multiple myeloma [sec · filed 2026-03-23].
- The company has incurred accumulated losses of $401 million through December 31, 2025, and expects to continue incurring losses [sec · filed 2026-03-23].
- As of December 31, 2025, BioLineRx had cash and equivalents of $0.6 million and total debt of $5.4 million [latest reported financials].
- The independent registered public accounting firm included a 'going concern' explanatory paragraph in its report on the financial statements for the year ended December 31, 2025 [sec · filed 2026-03-23].
- BioLineRx is advancing motixafortide for pancreatic cancer and other solid tumors, and developing GLIX1 [sec · filed 2026-03-23].
What works
- APHEXDA (motixafortide) received FDA approval in September 2023, providing a commercial-stage asset and potential for royalty and milestone revenue from out-licensing partners [sec · filed 2026-03-23].
- The company has a disciplined in-licensing strategy and experience in executing transactions with back-ended, success-based consideration [sec · filed 2026-03-23].
- BioLineRx is pursuing innovative therapies in oncology and rare diseases with a focus on candidates offering differentiation from current treatments [sec · filed 2026-03-23].
What to weigh
- BioLineRx has incurred significant losses since inception, with an accumulated deficit of $401 million as of December 31, 2025, and expects to continue losing money [sec · filed 2026-03-23].
- The company's independent auditor has issued a going concern opinion, indicating substantial doubt about its ability to continue as a viable entity [sec · filed 2026-03-23].
- Cash and equivalents were only $0.6 million as of December 31, 2025, with total debt of $5.4 million, raising concerns about near-term liquidity [latest reported financials].
- Revenue from APHEXDA product sales and milestones has not been sufficient to sustain operations, and there is no assurance of significant future revenue [sec · filed 2026-03-23].
From the filings
Quoted directly from source documents.
FDA approval of APHEXDA in September 2023
“Our first approved product is APHEXDA (motixafortide), a novel peptide for the treatment of stem-cell mobilization and solid tumors which, on September 8, 2023, was approved by the FDA for use in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.”
SEC filings · March 23, 2026
Going concern qualification by auditor
“Our independent registered public accounting firm has included a "going concern" explanatory paragraph in its report on our financial statements for the year ended December 31, 2025.”
SEC filings · March 23, 2026
Accumulated deficit of $401 million
“We have incurred accumulated losses in the amount of $401 million through December 31, 2025”
SEC filings · March 23, 2026
Catalyst timeline
- 2029-09-30 · Phase3_Topline — Topline results from a Phase III randomized, placebo-controlled study evaluating safety and tolerability of a candidate (likely motixafortide in pancreatic cancer).
Risks & what to watch (4)›
Key risks
- Going concern risk — Auditor's going concern opinion indicates substantial doubt about BioLineRx's ability to continue as a viable entity [sec · filed 2026-03-23].
- Liquidity and capital needs — Cash of $0.6M and debt of $5.4M as of 2025-12-31; company expects to need substantial future capital [latest reported financials; sec · filed 2026-03-23].
- History of losses — Accumulated deficit of $401M through 2025-12-31; may never achieve profitability [sec · filed 2026-03-23].
- Clinical and regulatory setbacks — Advanced clinical trials may fail despite earlier positive results; e.g., prior AML trial halted at interim [sec · filed 2026-03-23].
What to watch
- Ability to raise additional capital to fund operations and avoid liquidity crisis [sec · filed 2026-03-23].
- Commercial uptake and revenue generation from APHEXDA (motixafortide) in multiple myeloma [sec · filed 2026-03-23].
- Progress of motixafortide in pancreatic cancer and other solid tumor indications [sec · filed 2026-03-23].
- Development milestones for GLIX1 and potential out-licensing or partnership deals [sec · filed 2026-03-23].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run BioLineRx Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BioLineRx Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Cash runway data unavailable
D/E 0.75
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~1127d
No insider transactions in the last 180 days
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
11
Total value held
$67K
| Holder | Shares | Value |
|---|---|---|
| xtx topco ltd | 10,941 | $25K |
| susquehanna international group, llp | 10,200 | $24K |
| rhumbline advisers | 2,353 | $5K |
| bnp paribas financial markets | 1,800 | $4K |
| wells fargo & company/mn | 1,750 | $4K |
| citigroup inc | 1,728 | $4K |
| morgan stanley | 100 | $230 |
| osaic holdings, inc. | 26 | $59 |
| rockefeller capital management l.p. | 12 | $28 |
| danske bank a/s | 2 | $5 |
Showing top 10 of 11 institutional holders of BioLineRx Ltd.. Open the full 13F history after sign-in.
Short Interest
as of May 1, 2026- % of float
- 3.6%
- Days to cover
- 8.9
- Shares short
- 154,748
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BLRX short interestFrequently asked questions
What is the AI investment thesis for BioLineRx Ltd.?
BioLineRx Ltd. is a biopharmaceutical company focused on oncology and rare diseases, with one FDA-approved product (APHEXDA) and a pipeline including motixafortide for pancreatic cancer and GLIX1, but faces significant financial challenges with a going concern qualification and accumulated losses of $401 million.
What is BioLineRx Ltd.'s next catalyst?
BioLineRx Ltd.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase III, Randomized, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability " — expected September 30, 2029.
Who is the CEO of BioLineRx Ltd.?
Mr. Philip A. Serlin CPA, M.B.A. is the chief executive officer of BioLineRx Ltd. (BLRX).
Where is BioLineRx Ltd. headquartered?
BioLineRx Ltd. (BLRX) is headquartered in Hevel Modi'in, Israel.
What therapeutic areas does BioLineRx Ltd. focus on?
BioLineRx Ltd. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.